| Ytd | 129.91% | |
| 1y | 85.52% |
| Open | 2.69 | Prev Close | 2.65 | Low | 2.67 | High | 2.79 | Mkt Cap | 3.72M |
| Vol | 17.62K | Avg Vol | 20.55K | EPS | -21.20 | P/E | N/A | Forward P/E | -0.90 |
| Beta | 0.83 | Short Ratio | 1.95 | Inst. Own | 13.74% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 4.47 | 200-d Avg | 9.42 | 1yr Est | 13.00 |
BRTX News
Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regu
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market se
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers an
BioRestorative Therapies, Inc. (NASDAQ:BRTX) ("BioRestorative" or the "Company"), a
On August 7, 2026, BioRestorative Therapies, Inc. (the "Company") suspended, effective immed
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
https://ir.biorestorative.com/sec-filings/all-sec-filings/content/0001493152-26-033593/form8-k.htm
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")
US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, en
Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all sharehol
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")
Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patie
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")
BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.32) per share which missed t
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, mu
BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration ("FDA")
Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study
BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.33) per share which beat the
